Mohammed H. Alnazeer

Early Haematological Response and Short-Term Safety of Frontline Imatinib in Adults with Chronic Myeloid Leukaemia: A Retrospective Study in a Resource-Limited Setting

Sara S. Abdelrahim, Mohammed H. Alnazeer, Mawahib A. Mustafa, Safa A. Abdalla, Elkhanssa Abdelhameed Ahmed Elhag, Kannan O. Ahmed, Yasir S. Kheir, Elmoiz Babekir & Bashir A. Yousef · Journal of Advances in Medical and Pharmaceutical Sciences · 2026

Background: Imatinib mesylate is a tyrosine kinase inhibitor that has transformed the treatment of chronic myeloid leukaemia. However, information on its real-world use among sub-Saharan African populations remains limited. Aims: This study evaluated early haematological response...

Open access Research Article 10.9734/jamps/2026/v28i8879

Assessment of Pyrazinamide-Associated Hyperuricemia Among Multidrug-Resistant Tuberculosis Patients Receiving Pyrazinamide-Containing Regimens: A Retrospective Cross-Sectional Study from Sudan

Mayada E. Abdelrahman, Fatima S. Naim, Mawahib A. Mustafa, Elkhanssa Abdelhameed Ahmed Elhag, Mohammed H. Alnazeer, Kannan O. Ahmed, Orwa Siddig & Bashir A. Yousef · Journal of Advances in Medical and Pharmaceutical Sciences · 2025

Background: Tuberculosis (TB) is still one of the most important causes of morbidity and mortality worldwide. The problem multiplies whenever there is multidrug-resistant TB (MDR-TB), due to Mycobacterium tuberculosis susceptibility to both Rifampicin and Isoniazid. Pyrazinamide...

Open access Research Article 10.9734/jamps/2025/v27i12834